Background {#Sec1}
==========

Colorectal cancer is highly prevalent in Japan and Western countries, and the number of deaths resulting from malignant tumors is substantial \[[@CR1]--[@CR3]\]. Given the availability of various anticancer and molecular targeting agents during the past one to two decades, the survival prognosis of unresectable or recurrent colorectal cancer has been improved to approximately 30 months \[[@CR4]\]. The current National Comprehensive Cancer Network (NCCN) guideline recommends a systemic chemotherapy regimen comprising a FOLFOX/FOLFIRI/FOLFOXIRI (folinic acid (leucovorin (LV)), 5-fluorouracil (5-FU), and oxaliplatin/irinotecan) regimen plus molecular-target treatments (an anti-vascular endothelial growth factor, anti-epidermal growth factor receptor, aflibercept, or anti-multi-kinase antibody therapy) for unresectable/recurrent colorectal cancers \[[@CR5]\]. However, no effective therapies have been established for cases refractory to the recommended treatment regimens. The liver is the most frequent site of colorectal cancer recurrence \[[@CR6], [@CR7]\]. Such tumors will eventually lead to hepatic dysfunction and failure, frequently causing death. Accordingly, survival might be prolonged by using an effective treatment against hepatic metastatic lesions. Although transcatheter arterial chemoembolization, radiofrequency ablation, external beam radiation therapy, and hepatic artery infusion are currently considered the primarily local liver treatment modalities \[[@CR8]--[@CR13]\], hepatic artery infusion did not yield any survival benefit in a comparative study of systemic chemotherapy and therefore has not often been used \[[@CR14], [@CR15]\]. However, in cases of solitary hepatic tumors, hepatic artery infusion can deliver high concentrations of anticancer drugs to the tumor to yield substantial tumor shrinkage. Therefore, this modality is considered significantly useful.

In the following paragraphs, we present our findings regarding the efficacy of hepatic artery infusion for unresectable colorectal cancer metastatic liver lesions and impending hepatic failure in patients who were unresponsive to systemic chemotherapy. Furthermore, we prepared and exposed anticancer drug-resistant colorectal cancer cells to high anticancer drug concentrations and observed the induction of apoptosis and cell death.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

The 10 subjects had progressive disease (PD), unresectable colorectal cancer that was treated with FOLFOX, FOLFIRI, anti-VEGF antibody, or anti-EGFR antibody therapy according to the guideline and hepatic metastases that were considered a prognosis-determining factor at the First Department of Surgery of the University of Fukui between 2011 and 2014 (Table [1](#Tab1){ref-type="table"}).Table 1Patient characteristicsAgePrimaryExtraK-Ras mutUGT1A1Previous chemotherapy hepatic lesions1. 60SLung−Wild5FU, L-OHP, CPT-11 anti-VEGF/EGFR Ab2. 71D−Homo5FU, L-OHP, anti-VEGF/EGFR Ab3. 69D+Wild5FU, L-OHP, CPT-11, Anti-VEGF Ab4. 63TPeritoneum−Wild5FU, L-OHP, CPT-11, anti-VEGF/EGFR Ab5. 55R+Wild5FU, L-OHP, CPT-11, anti-VEGF Ab6. 81CBone+Hetero5FU, L-OHP7. 55RLung−Hetero5FU, L-OHP, CPT-11, anti-VEGF Ab8. 56DLung−Hetero5FU, L-OHP, CPT-11, anti-VEGF/EGFR Ab9. 56R−Wild5FU, L-OHP, CPT-11, anti-VEGF Ab10. 57R−Wild5FU, L-OHP, CPT-11, anti-VEGF/EGFR Ab*C* cecum, *T* transverse, *D* descending, *S* sigmoid, *R* rectum)Table 2Results of HAIC treatmentHAIC (times)ResponseNew extrahepatic lesionsOverall survival (months)1.12SD--52.18PR--93.34PRPeritoneum, brain124.44PR--165.7^a^SDPeritoneum, lung, bone46.3^a^PDLung27.16SD--11^b^8.8SD--39.6PDBone9^b^10.6PD--3^ba^Discontinuation of HAIC, 5. Interstitial pneumonia, 6. Malaise^b^AliveTable 3Tumor responseNo. of patientsResponseDisease control rate (%)C.R.P.R.S.D.P.D.10034370 %Table 4Patients' complaintsPatientHAICPre-Post-1.Difficulties with walking, leg edema, malaiseRecovered during 4 months2.Malaise, appetite lossRecovered during 6 months3.Leg edemaRecovered during 9 months4.Leg edemaRecovered during 14 months5.Leg edemaRecovered during 2 months6.General fatigue, leg edema, low back painNo change7.Epigastric pain, leg edemaRecovered during 6 months8.Leg edemaRecovered during 2 months9.----10.MalaiseRecovered during 3 monthsTable 5Toxicity (CTCAE v4.0)Grades 1--2Grade 3--4Diarrhea0 (0 %)0 (0 %)Anorexia1 (10 %)0 (0 %)Malaise0 (0 %)1 (10 %)Neutropenia1 (10 %)0 (0 %)Thrombopenia0 (0 %)0 (0 %)Interstitial pneumonia0 (0 %)1 (10 %)

Hepatic artery infusion therapy {#Sec4}
-------------------------------

Hepatic infusion tube placement was performed according to the Seldinger method in order to insert a catheter with a side hole via the right femoral artery; the tip was placed at the gastroduodenal artery, and the drug was administered into the hepatic artery via the catheter side hole. A coiling procedure was performed to prevent drug influx into the gastroduodenal artery (Fig. [1](#Fig1){ref-type="fig"}). Angiography was performed to allow drug influx into the hepatic artery. The chemotherapy regimen comprised once weekly 5-FU (500 mg/m^2^ for 5 min) and LV (200 mg/m^2^ for 2 h). Four 6-week courses were administered. The efficacy was evaluated using computed tomography (CT) after four courses; the efficacy was evaluated in accordance with the Response Evaluation Criteria in Solid Tumors, and adverse reactions were assessed according to assessed on the basis of RECIST (version 1.1) criteria \[[@CR16]\] and National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 \[[@CR17]\].Fig. 1Hepatic artery infusion therapy. Hepatic infusion tube placement was performed according to the Seldinger method. The tip was placed at the gastroduodenal artery, and the drug was administered into the hepatic artery via the catheter side hole. A coiling procedure was performed to prevent drug influx into the gastroduodenal arteryFig. 2Overall survival curves of patients with unresectable hepatic metastases and impending hepatic failure treated with HAIC therapy. HAIC group had a 45 % rate of surviving 10 months, and median survival time(MST) is 9 months

Chemicals {#Sec5}
---------

5-FU was dissolved in distilled water, and the pH was adjusted to 7.0 according to the manufacturer's recommendation (Sigma Chemical Co. MO, USA).

Resistant cell lines {#Sec6}
--------------------

Colon cancer cells were seeded onto a 6-cm dish at 1×10^5^ and incubated for 24 h. The cells were treated with 5-FU of 0.1 microgram/ml for 7 days. We established 5-FU-resistant cell lines.

5-FU treatment {#Sec7}
--------------

5-FU-resistant colon cancer cells were seeded onto a 24-well plate at 1×10^4^ and incubated with 5-FU for 24 h.

Cell viability {#Sec8}
--------------

Cell death and apoptosis was detected by cytometry using Annexin-V-FLUOS staining Kit (Roche, Germany). After cells were washed in PBS, we detected red cells under a fluorescent microscope.

Statistical analyses {#Sec9}
--------------------

Survival time was estimated by using Kaplan-Meier method. The characteristics of two treatment arms were evaluated by *t* test. Two-sided *p* \< 0.05 were considered significant.

Results {#Sec10}
=======

Efficacy {#Sec11}
--------

Of the 10 subjects, 3 (30 %) showed partial response and 4 (40 %) showed no change according to computed tomography imaging findings obtained after hepatic artery infusion. The disease control rate was 70 %. A biochemical blood evaluation prior to hepatic artery infusion revealed abnormal alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, and alkaline phosphatase levels in all of the subjects, indicative of hepatic dysfunction. After hepatic artery infusion, the abnormal hepatic function levels improved in all of the subjects (Table [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}).

Subjects' performance statuses {#Sec12}
------------------------------

Regarding the subjective symptoms, six patients experienced alleviation of leg edema. In particular, one subject who had difficulty walking was able to walk and perform housework. Four subjects experienced improvements in or disappearance of symptoms (Table [4](#Tab4){ref-type="table"}).

Survival time {#Sec13}
-------------

The survival time ranged from 2 to 16 months (median, 9 months). An extrahepatic metastatic lesion was found in four patients after initiating hepatic artery infusion; this lesion did not affect the prognosis.

Adverse reactions {#Sec14}
-----------------

Grade 1 anorexia and neutropenia were observed, but neither was serious. The symptoms of systemic malaise and anorexia that were experienced by the nine subjects during systemic chemotherapy were alleviated during the course of hepatic artery infusion (Table [5](#Tab5){ref-type="table"}).

Annexin V staining of the 5-FU-resistant colon cancer cell line exposed to high 5-FU concentrations {#Sec15}
---------------------------------------------------------------------------------------------------

A 5-FU (0.01 μg/mL)-resistant colon cancer cell line was exposed to 0.5--500 μg/mL 5FU and stained according to the annexin V method in order to determine the number of apoptotic cells. The results are shown in Fig. [3](#Fig3){ref-type="fig"}. The number of stained cells increased significantly along with increased 5-FU concentrations in all of the 5FU-resistant colon cancer lines, possibly indicating apoptosis or cell death. However, the numbers of stained cells at any concentration were fewer than those observed in populations of 5-FU-susceptible colon cancer cells.Fig. 35-FU-resistant colon cancer cell line exposed to high 5-FU concentrations. **a** 5-FU-resistant HCT116 colon cancer cells (1 × 10^4^) were seeded onto 24 wells and were incubated with 5-FU for 24 h. Cell death and apoptosis was detected by cytometry using Annexin-V-FLUOS staining Kit. After washing cancer cells, the staining cell number were counted at ×200 magnification. *Left panel*: The cells were photographed at ×200 magnification. *Right panel* ANNEXIN-V-FLUOS staining cells. **b** The number of stained cells. Each *bar* represents the mean number of stained cells; *error bar* is SD. \**p* \< 0.01

Discussion {#Sec16}
==========

Hepatic metastasis is considered a prognosis-determining factor of colorectal cancer \[[@CR2], [@CR18]\]. Hepatic metastasis is observed in approximately 10 % of initial surgery cases, and 4 % of such cases are found to have multiple metastases throughout the liver \[[@CR19], [@CR20]\]. According to recent reports, the survival duration of liver metastatic colorectal cancer patients is prolonged when curative surgery is possible for not only the primary lesion but also the hepatic metastases \[[@CR21]--[@CR23]\]. However, colorectal cancers with multiple metastases throughout the liver must be treated via chemotherapy. Although systemic and arterial administrations are possible chemotherapeutic dosing routes, systemic administration has been recommended in the NCCN guideline and has therefore been selected in many clinical cases \[[@CR5]\]. Nevertheless, no effective therapies are available for chemotherapy-resistant cases. Among such cases, patients for whom hepatic metastasis represented the greatest prognosis-determining risk factor were selected as subjects in the present study in order to examine the effects of hepatic artery infusion. The following are explanations of the pharmacological efficacy of hepatic artery infusion: (1) because higher drug concentrations can reach the tumor, compared with those achieved via intravenous infusion, artery infusion acts more effectively against tumor cells; (2) because smaller drug amounts enter non-tumor tissues throughout the body, the drug distribution in the organs other than the liver is reduced \[[@CR24]\], possibly leading to fewer adverse reactions and higher maximum tolerable dosages. Hepatic arterial infusion is thought to be more effective than systemic administration for the treatment of liver diseases.

In the present study, disease control was temporarily achieved in seven of 10 cases of systemic chemotherapy-resistant unresectable colorectal cancers with hepatic metastasis and impending hepatic failure. Furthermore, subjective symptoms were improved, thus yielding a higher QOL and suggesting the effectiveness of this therapy. The incidence and grades of the adverse reactions were lower in comparison compared with systemic chemotherapy and the FOLFIRI and FOLFOX regimens.

The greatest cause of metastatic lesion growth inhibition in response to hepatic arterial infusion in the study patients under the described conditions was the increased drug concentrations in the target organ, in light of the experimental finding that higher concentrations of anticancer drugs could induce apoptosis and death in an anticancer drug-resistant cancer cell line.

Conclusions {#Sec17}
===========

The efficacy of hepatic arterial infusion was observed in unresectable colorectal cancer patients with prognosis-determining hepatic metastases that were resistant to molecular-targeted agents and the FOLFOX and FOLFIRI regimens. This concept supported the finding that apoptosis and cell death could be induced in anticancer drug-resistant colorectal cancer cells in a drug concentration-dependent manner.
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